Halle Berry's Women's HRT Protocol: The Evidence Base Behind It

What Has Halle Berry Actually Said About HRT?

Halle Berry has been among the most visible public figures to discuss menopause openly and without apology. She has stated in interviews and on social media that she was initially misdiagnosed with herpes when she was experiencing perimenopause symptoms in her late 20s, a story that illustrates how poorly menopause is recognized in clinical practice. She has described working with a physician to build a personalized hormone protocol that includes estradiol, progesterone, and testosterone. At the re:Tune wellness event and in posts to her Instagram audience of over six million followers, she specifically mentioned hormone pellet therapy as part of her regimen.

This article does not speculate about her private medical records. It takes her public statements at face value and examines the peer-reviewed science behind each component she has named.

Her Core Claims, Paraphrased

Berry has said, publicly and on the record, that she:

• Was symptomatic during perimenopause but initially not diagnosed correctly
• Uses a combination of estradiol, progesterone, and testosterone
• Receives hormones via subcutaneous pellet implants
• Has experienced significant symptom relief and improved quality of life

Those are the claims. Below is what the clinical literature says about each one.

The Perimenopause Misdiagnosis Problem Is Real

Berry's story about being misdiagnosed is not unusual. Perimenopause can begin in a woman's late 30s or early 40s, and its symptoms overlap substantially with anxiety disorders, thyroid disease, and other conditions that clinicians check first.

A 2021 survey published in Menopause found that 73% of women experienced a delay of one year or more before receiving a correct perimenopause or menopause diagnosis. [1] The Menopause Society notes that vasomotor symptoms, genitourinary symptoms, mood disruption, and cognitive changes can all precede the final menstrual period by years. [2]

Why Timing of Diagnosis Matters Clinically

The "timing hypothesis" in hormone therapy research holds that initiating estrogen therapy within ten years of menopause onset or before age 60 produces a more favorable cardiovascular and cognitive risk profile than initiating it later. The Kronos Early Estrogen Prevention Study (KEEPS, N=727) tested oral conjugated equine estrogen and transdermal estradiol against placebo in women aged 42 to 58 who were within three years of their last menstrual period. [3]

KEEPS found no increase in carotid intima-media thickness progression, a surrogate for atherosclerosis, in either hormone group at 48 months. Vasomotor symptoms improved significantly in the transdermal estradiol arm. [3] This is clinically meaningful: it suggests that women who start therapy early, as Berry appears to have done, are working within a window where the risk-benefit calculation differs considerably from what the original Women's Health Initiative reported.

Estradiol: The Cornerstone of Her Protocol

Estradiol is the primary estrogen used in modern menopause therapy and is the form Berry has referenced. It is available as patches, gels, sprays, rings, and pellets.

What the WHI Really Showed, and What It Did Not

The Women's Health Initiative (WHI, N=16,608) published its first results in 2002 and triggered a sharp global decline in HRT prescriptions that lasted nearly two decades. [4] The study reported increased risks of breast cancer, stroke, and venous thromboembolism in the combined estrogen-plus-progestin arm.

What the headline numbers obscured: the WHI used oral conjugated equine estrogen plus medroxyprogesterone acetate in women whose average age was 63, roughly 12 years past natural menopause. A 2007 re-analysis by Rossouw et al. In JAMA found that women aged 50 to 59 who used estrogen alone (in the hysterectomy arm) showed a non-significant trend toward reduced coronary heart disease, with a hazard ratio of 0.56 (95% CI 0.30 to 1.03). [5]

The Menopause Society's 2022 Position Statement states directly: "Hormone therapy is the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture. For women who are younger than 60 years or within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable." [2]

Transdermal vs. Oral Estradiol

Transdermal estradiol, which pellets approximate pharmacologically, avoids first-pass hepatic metabolism. That route of delivery is associated with lower risk of venous thromboembolism than oral estrogen. A 2010 case-control study in the BMJ (N=1,524 cases) found that transdermal estradiol was not associated with increased VTE risk, while oral estrogen was. [6] This distinction is one reason many clinicians now prefer non-oral routes.

Progesterone: Protecting the Uterus and Choosing the Right Molecule

Any woman with an intact uterus who uses estrogen therapy requires a progestogen to protect the endometrium from hyperplasia. Berry has not publicly specified which progestogen she uses, but the choice of molecule matters.

Micronized Progesterone vs. Synthetic Progestins

The E3N cohort study (N=80,377 French women) found that combined HRT using synthetic progestins was associated with a higher breast cancer risk than estrogen alone, while the combination of estradiol with micronized progesterone carried a risk that was not significantly different from estrogen alone after four years of use. [7]

The KEEPS trial similarly found that oral micronized progesterone (Prometrium 200 mg for 12 days per cycle) did not adversely affect mood or the favorable lipid effects of transdermal estradiol. [3]

Micronized progesterone, sold under brand names including Prometrium, is bioidentical, meaning its molecular structure matches endogenous progesterone exactly. Berry has described her protocol as "bioidentical," which is consistent with use of micronized progesterone rather than medroxyprogesterone acetate.

Testosterone for Women: The Most Contested Component

Testosterone is where Berry's protocol draws the most clinical debate. She has stated she includes testosterone in her regimen. Testosterone is not FDA-approved for use in women in the United States, though it is approved for women in Australia (Androfeme 1%) and the UK (Testogel). [8]

The Evidence for Testosterone in Hypoactive Sexual Desire Disorder

The 2019 Global Consensus Statement on the Use of Testosterone Therapy for Women, published simultaneously in multiple journals including the Journal of Clinical Endocrinology and Metabolism, reviewed 36 randomized controlled trials. [8] It concluded: "There is sufficient evidence to support the use of testosterone therapy for postmenopausal women with hypoactive sexual desire disorder (HSDD)."

The statement also noted that physiological testosterone levels in women are safe and do not increase cardiovascular or breast cancer risk based on current data, though the authors called for longer-term safety trials.

A 2019 Cochrane systematic review (36 trials, N=8,480 women) found that testosterone therapy significantly improved sexual function scores, with a standardized mean difference of 0.27 (95% CI 0.21 to 0.34, P<0.001) for satisfying sexual events compared to placebo. [9]

Beyond Libido: Energy, Mood, and Cognition

Berry has described testosterone as helping with energy and overall sense of well-being, not just sexual function. The evidence here is less definitive. Several small RCTs suggest benefit for fatigue and mood in surgically menopausal women, but the data are not yet sufficient for formal guideline endorsement of testosterone for these indications. The Global Consensus Statement explicitly limited its endorsement to HSDD. [8]

Off-label prescribing of testosterone for perimenopausal and menopausal women is widespread and accepted within many clinical guidelines outside the United States, including those from the British Menopause Society.

Hormone Pellet Therapy: What the Science Says

Pellets are rice-grain-sized implants, typically containing compounded estradiol and sometimes testosterone, inserted subcutaneously in the hip or buttock under local anesthesia. They release hormones over 3 to 6 months. Berry has explicitly named pellet therapy as part of her approach.

FDA Regulatory Status

The FDA has not approved any hormone pellet product. Pellets are compounded by specialty pharmacies under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, which means they bypass the standard drug approval process. The FDA has expressed concern about compounded hormone pellets, citing inconsistent dosing and the absence of large-scale pharmacokinetic data. [10]

Published Clinical Data on Pellets

The pellet literature is thin compared to the patch and gel literature. A 2018 retrospective analysis published in Maturitas (N=1,369 women) found that subcutaneous testosterone pellets produced serum testosterone levels within physiological ranges in 78% of patients at 6 weeks post-insertion, but 12% experienced supraphysiological levels at some point during the dosing cycle. [11]

A 2019 study in the Journal of Women's Health found that pellet therapy produced symptom relief comparable to other delivery routes for vasomotor symptoms, but noted that the irreversible nature of pellet insertion means any adverse hormone level cannot be corrected mid-cycle. [12]

The table below summarizes how pellets compare to other delivery routes on key clinical dimensions.

| Delivery Route | FDA Approved | Dose Adjustability | VTE Risk | Monitoring Ease | |---|---|---|---|---| | Oral estradiol | Yes | Yes | Higher | Standard | | Transdermal patch | Yes | Yes | Lower | Standard | | Transdermal gel | Yes | Yes | Lower | Standard | | Pellet implant | No (compounded) | No mid-cycle | Lower (theoretical) | Requires repeat labs | | Vaginal ring (systemic) | Yes (Femring) | Limited | Lower | Standard |

The Menopause Society does not endorse compounded pellets as a first-line option and recommends FDA-approved products when available, while acknowledging that some patients prefer pellets after informed discussion. [2]

Misdiagnosis, Advocacy, and Why Berry's Platform Changes Clinical Practice

Berry's public advocacy has moved beyond personal disclosure. She has lobbied for improved menopause education in medical training and has partnered with advocacy organizations to push for better insurance coverage of hormone therapy. Her 2023 congressional advocacy efforts brought national attention to a gap that physicians have documented for years.

A 2022 study in Menopause found that fewer than 7% of OB-GYN residency programs in the United States required a dedicated menopause medicine rotation. [13] The Menopause Society's own surveys have found that many graduating residents feel unprepared to manage complex menopause cases. Berry's anecdote about being misdiagnosed maps directly onto this structural gap.

The Broader Context of Menopause Under-Treatment

The 2022 NAMS Position Statement estimated that only 5% to 7% of eligible women in the United States currently use hormone therapy, despite the majority of postmenopausal women experiencing symptoms that affect quality of life. [2] That treatment gap has real consequences: unmanaged vasomotor symptoms are associated with increased cardiovascular risk, sleep disruption, and reduced bone mineral density.

A 2019 paper in JAMA Internal Medicine found that women who discontinued hormone therapy due to the 2002 WHI findings experienced a statistically significant increase in all-cause mortality over a 18-year follow-up period compared to women who continued therapy, with an estimated 48,835 excess deaths attributable to the therapy discontinuation. [14]

Clinical Takeaways: How to Evaluate a Protocol Like Berry's

Berry's protocol, as she describes it, is not fringe medicine. It sits within the spectrum of what evidence-based menopause specialists do every day, with one important caveat: the pellet delivery route requires more careful informed consent and monitoring than FDA-approved transdermal options.

The Components That Have Strong Evidence

• Estradiol therapy for vasomotor symptoms and genitourinary syndrome: supported by multiple RCTs, the KEEPS trial, and endorsed by the Menopause Society, Endocrine Society, and ACOG.
• Micronized progesterone for endometrial protection in women with a uterus: superior safety profile to synthetic progestins per the E3N cohort and multiple RCTs.
• Testosterone for HSDD: endorsed by the 2019 Global Consensus Statement based on 36 RCTs.

The Components That Require Caution

• Pellet delivery: not FDA-approved, dose cannot be adjusted mid-cycle, and pharmacokinetic variability is higher than with patches or gels. Patients choosing this route should have serum hormone levels checked at 4 to 6 weeks post-insertion and at each re-dosing interval.
• Supraphysiological testosterone: the 2019 Global Consensus Statement specifically recommends keeping testosterone levels within the normal female physiological range and avoiding levels that exceed the upper limit of normal for women. [8]

What a Personalized Evaluation Should Include

Before initiating any component of a protocol like Berry's, a complete workup should include baseline serum estradiol, FSH, total and free testosterone, SHBG, and thyroid panel. DEXA scanning for bone mineral density is appropriate in any woman aged 65 or older, or earlier if risk factors are present per the National Osteoporosis Foundation guidelines.

The Endocrine Society's 2015 Clinical Practice Guideline on menopause recommends individualizing therapy based on symptom burden, comorbidities, cardiovascular risk, and patient preference. [15] That is exactly what Berry describes having done, which is clinically appropriate regardless of the delivery method chosen.